Kerendia 20 mg film-coated tablets
Sponsors
Universitair Medisch Centrum Groningen, Bayer AG, Universitaetsklinikum Erlangen AöR, The George Institute For Global Health, Region Midtjylland
Conditions
AlbuminuriaChronic Kidney DiseaseChronic kidney diseaseChronic kidney disease in type 2 diabetes mellitusType 2 diabetestype 2 diabetes mellitus
Phase 2
FINESSE; Optimization of albuminuria lowering therapies to individual patients with CKD using FINErenone and SEmaglutide (FINESSE-CKD)
RecruitingCTIS2023-506434-69-00
Start: 2025-02-11Target: 36Updated: 2024-08-28
(21839) A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.
CompletedCTIS2023-506981-30-00
Start: 2022-05-25End: 2025-02-26Target: 220Updated: 2024-09-24
Phase 3
Effects of Finerenone on Renal Hemodynamics and Oxidative Stress
CompletedCTIS2023-508266-15-00
Start: 2024-01-18End: 2025-11-25Target: 75Updated: 2024-08-16
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)
Not yet recruitingCTIS2024-520253-21-00
Target: 150Updated: 2025-09-16
Phase 4
Optimization of Albuminuria-Lowering Therapies for Individual Patients with Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial
RecruitingCTIS2023-508585-15-00
Start: 2024-07-29Target: 10Updated: 2024-04-25
Semaglutide and Finerenone for Kidney and Vascular Protection in CKD
RecruitingCTIS2025-522503-18-00
Start: 2025-10-27Target: 160Updated: 2025-09-09